cellmid-4

Novel approaches to treating important diseases


Cellmid has two therapeutic subsidiaries:  

 

1. 

Lyramid: Leverages therapeutic antibodies against midkine in order to treat cancer and inflammatory diseases 

 

2.

Kinera: Harnesses the anti-apoptotic and acute protective effects of midkine protein following ischemic injury e.g. heart attack